Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis

Qiu, Xia; Xiong, Tao; Su, Xiaojuan; Qu, Yi; Ge, Long; Yan, Ye; Zeng, Yan; Li, Weihua; Hu, Peng; Mu, Dezhi

doi:10.1186/s12879-019-4466-5

Cited by 23 publications

(17 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNFα and IP-10/CXCL10 were recently identified as two biomarkers among a 4-biomarker signature predictive of incident versus prevalent TB in a less immunosuppressed cohort of PLWH ( 51 ). IP-10/CXCL10, a chemokine secreted in response to INFγ, has been established as a biomarker of latent and active TB ( 52 – 54 ). IP-10/CXCL10 has also been identified as predictive of incident TB in two additional studies of PLWH ( 55 , 56 ).…”

Section: Discussionmentioning

confidence: 99%

Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV

et al. 2021

View full text Add to dashboard Cite

Tuberculosis (TB) accounts for disproportionate morbidity and mortality among persons living with HIV (PLWH). Conventional methods of TB diagnosis, including smear microscopy and Xpert MTB/RIF, have lower sensitivity in PLWH. Novel high-throughput approaches, such as miRNAomics and metabolomics, may advance our ability to recognize subclinical and difficult-to-diagnose TB, especially in very advanced HIV. We conducted a case-control study leveraging REMEMBER, a multi-country, open-label randomized controlled trial comparing 4-drug empiric standard TB treatment with isoniazid preventive therapy in PLWH initiating antiretroviral therapy (ART) with CD4 cell counts <50 cells/μL. Twenty-three cases of incident TB were site-matched with 32 controls to identify microRNAs (miRNAs), metabolites, and cytokines/chemokines, associated with the development of newly diagnosed TB in PLWH. Differentially expressed miRNA analysis revealed 11 altered miRNAs with a fold change higher than 1.4 or lower than -1.4 in cases relative to controls (p<0.05). Our analysis revealed no differentially abundant metabolites between cases and controls. We found higher TNFα and IP-10/CXCL10 in cases (p=0.011, p=0.0005), and higher MDC/CCL22 in controls (p=0.0072). A decision-tree algorithm identified gamma-glutamylthreonine and hsa-miR-215-5p as the optimal variables to classify incident TB cases (AUC 0.965; 95% CI 0.925-1.000). hsa-miR-215-5p, which targets genes in the TGF-β signaling pathway, was downregulated in cases. Gamma-glutamylthreonine, a breakdown product of protein catabolism, was less abundant in cases. To our knowledge, this is one of the first uses of a multi-omics approach to identify incident TB in severely immunosuppressed PLWH.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Current clinical diagnosis of TB still relies on a traditional approach that includes acid-fast bacillus (AFB) smears, nucleic acid amplification (NAA) (e.g. Xpert MTB/RIF or Xpert MTB/RIF Ultra), and culture of M. tuberculosis from sputum and other respiratory specimens, in addition to evaluation of clinical symptoms 6 . However, sputum smears have very low sensitivity (10–20%), and MTB culture lacks sensitivity and requires 2–8 weeks to obtain results 7 .…”

Section: Introductionmentioning

confidence: 99%

Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB

Liu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Bacterial culture of M. tuberculosis (MTB), the causative agent of tuberculosis (TB), from clinical specimens is the gold standard for laboratory diagnosis of TB, but is slow and culture-negative TB cases are common. Alternative immune-based and molecular approaches have been developed, but cannot discriminate between active TB (ATB) and latent TB (LTBI). Here, to identify biomarkers that can discriminate between ATB and LTBI/healthy individuals (HC), we profiled 116 serum samples (HC, LTBI and ATB) using a protein microarray containing 257 MTB secreted proteins, identifying 23 antibodies against MTB antigens that were present at significantly higher levels in patients with ATB than in those with LTBI and HC (Fold change > 1.2; p < 0.05). A 4-protein biomarker panel (Rv0934, Rv3881c, Rv1860 and Rv1827), optimized using SAM and ROC analysis, had a sensitivity of 67.3% and specificity of 91.2% for distinguishing ATB from LTBI, and 71.2% sensitivity and 96.3% specificity for distinguishing ATB from HC. Validation of the four candidate biomarkers in ELISA assays using 440 serum samples gave consistent results. The promising sensitivity and specificity of this biomarker panel suggest it merits further investigation for its potential as a diagnostic for discriminating between latent and active TB.

show abstract

“…In recent years, a milieu of inflammatory factors, cytokines and chemokines have been found to be useful in immune diagnosis of TB and monitoring the efficacy of therapy, including C-reactive protein (CRP), interferon-γ [IFN-γ], interleukin-6 [IL-6], tumor necrosis factor-α [TNF-α] or chemokine interferon-gamma inducible protein-10 (IP-10) [9][10][11][12] Some hematological inflammatory markers of TB patients, such as white blood cell (WBC) counts, mean platelet volume (MPV), neutrophil counts (NEU) have provided enlightening insights into monitoring the outcomes of tuberculosis treatment [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…IP-10 has been widely evaluated as a biomarker for TB and it has been reported to be expressed at 100-fold higher levels than IFN-γ with a greater detection reproducibility [ 12 ]. IP-10 is secreted by several cell types such as monocytes or neutrophils, and induce the chemoattraction of other cells including monocytes and T cells at inflammatory sites [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results

et al. 2021

View full text Add to dashboard Cite

Pro-inflammatory mediators play an important role in the pathogenesis of pulmonary tuberculosis. Consecutively, 26 pulmonary tuberculosis patients were enrolled in our study based on the exclusion criteria. We have used Spearman’s correlation analysis, hierarchical clustering and regression modelling to evaluate the association of 11 biomarkers with culture status after antituberculosis treatment. The results of our study demonstrated that six inflammatory biomarkers of 11, C-reactive protein (CRP), white blood cells (WBC), neutrophils, interferon gamma inducible protein 10, C-reactive protein (CRP) to albumin ratio (CAR) and neutrophil to albumin ratio (NAR), were significantly associated with culture negativity. The predictive ability of a composite model of seven biomarkers was superior to that of any single biomarker based on area under the receiver operating characteristic curve (AUC) analysis, indicating an excellent prediction efficacy (AUC:0.892; 95% CI:0.732-1.0). We also found that the highest significant trends and lower levels of CRP and IP-10 were observed in the two-month treated tuberculosis (TB) patients. We believe that our study may be valuable in providing preliminary results for an additional strategy in monitoring and management of the clinical outcome of pulmonary tuberculosis. Using a panel of predictors added a superior value in predicting culture status after anti-TB therapy.

show abstract

Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis

Cited by 23 publications

References 42 publications

Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV

Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV

Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB

Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results

Contact Info

Product

Resources

About